The global live cell imaging market size is projected to reach USD 2.8 billion by 2025 from USD 1.8 billion in 2020, at a CAGR of 8.8% during the forecast period. The growing adoption of high-content screening techniques in drug discovery and rising incidence of cancer, primarily drives the market for live cell imaging. The growth in research funding, and rising government funding in regenerative medicine research will also contribute to market growth in the coming years. However, the high cost of high cost of high-content screening systems is restraining the growth of live cell imaging market.
Some of the key players competing in the live cell imaging market are Danaher Corporation (US), Carl Zeiss AG (Germany), Nikon Corporation (Japan), Olympus Corporation (Japan), PerkinElmer, Inc. (US), GE Healthcare (US), Bruker Corporation (US), Thermo Fisher Scientific Inc. (US), Sartorius AG (Germany), Oxford Instruments (UK), BioTek Instruments (US), Etaluma, Inc. (US), CytoSMART Technologies (Netherlands), NanoEnTek Inc. (Korea), Phase Focus Limited (UK), Tomocube, Inc. (South Korea), Phase Holographic Imaging PHI AB (Sweden), BD Biosciences (US), Sony Biotechnology, Inc. (US), Merck KGaA (Germany), KEYENCE Corporation (Japan), ibidi GmbH (Germany), Bio-Rad Laboratories (US), Logos Biosystems (South Korea), and Nanolive SA (Switzerland). These players have adopted various growth strategies such as partnerships, agreements, collaborations, acquisitions; expansions; and new product launches to increase their presence in the global live cell imaging market.
To know about the assumptions considered for the study download the pdf brochure
Danaher Corporation (US) was the leading player in the live cell imaging market and accounted for the largest share in 2019. The company is a global leader in the live cell imaging and has been operating in the market for about 50 years. Through its subsidiaries, Leica Microsystems and Molecular Devices, the company offers a wide range of live cell imaging products, such as microscopes, LAS X imaging software, and cameras, to keep cells viable for obtaining artifact-free data in long-term imaging. Danaher Corporation focuses on organic and inorganic growth strategies to sustain its market position and enter high-growth markets.
Carl Zeiss (Germany) held the second-largest share of the global live cell imaging market. Its position in the market can be attributed to its robust product portfolio and reliable distribution channel across the world. It provides a wide range of live cell imaging instruments, consumables, and software in the life science research and pharmaceutical & biotherapeutic development. To maintain its position in the market, the company focuses on expanding its product portfolio through strategies such as product launches, agreements, partnerships, collaboratons, and expansions. For instance, in April 2020, Danaher Corporation launched STELLARIS, a confocal microscopy platform, to capture 3D images of living cells and tissues.
Live Cell Imaging Market by Product (Instruments, Consumables, Software, Services) Application (Cell Biology, Drug Discovery) Technology (Time-lapse Microscopy, FRET) End User (Contract Research Organization, Research Institutes) - Global Forecast to 2025
Mr. Aashish Mehra
630 Dundee Road
Northbrook, IL 60062
USA : 1-888-600-6441
This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.SEND ME A FREE SAMPLE